Completed
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT05509699
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Extensive-stage Small Cell Lung Cancer, +8 more
- Locations
-
- Chinese PLA General Hospital Beijing, China